Some more: Does anyone know what a "KOL" is? Sounds

New Post Public Reply Private Reply Replies (1) Message Board
Bravo16
309
Some more: Does anyone know what a "KOL" is?

Sounds like a spokesperson of sorts and the way Joe describes it here is that the ones he uses are doing it essentially for free because they know how good GNBT's the science

Joseph Moscato

only people to me are KOLS I listen to, academia is never something a drug developer like myself or my peers would ever take seriously, listen to, and even consider, and that’s just the way it is, if it’s cancer I want to know all the drugs you’ve been part of developing, does not matter if they have been commercialized or not, what matters is that clinician being on the front line and have participated because of their knowledge in all drug trials, why, they have the knowledge in the pathway, they have the experience and know what works and what doesn’t in regard to mechanism of action without them you got nothing, a KOL also gets paid an honorarium of about 1,500.00 a year and his expenses paid to go to conferences and talk you up and represent the science, if you have the best of the best on your team for this you know they believe in your science and they want to be part of the next big thing, then there is those same kols if the get paid big money or consideration that tells you something else, it means they are not sure about your science and want to be compensated for their time because it won’t probably be the next big thing, then their are the experts or supposed experts with big names that aren’t in let’s say breast cancer but the biggest in another area, or their a surgeon, big red flag that means they make a lot and your science is garbage, in addition as it pertains the the best surgeons on the planet you see one of them in science for sure they are getting paid big, huge red flag, why would a drug developer have a surgeon on board, cause they don’t know the business, that’s never taken seriously in fact it’s a joke, surgeons cut things out, they do not treat so why are they in drug development, because of the almighty dollar and lack of knowledge of the companies management team, the goal is always to partner with big pharma when the time is right and these signals will get your thrown out an office rather then sit down let’s discuss your science, so no I do not take any kind of Dr’s word or hyperbole who is not a KOL in the field you are developing that drug in, I just normally laugh!

Jay Colavita

I'm impressed with the explanation about the distinction of whether the opinion is actually factual or monetary driven. Everyone has an opinion and some are assholes and stink! I know you and you demand exceptional accomplishments only surrounding yourself with the best. I have faith under your direction your team will provide the best long term solution to this dilemma.

Joseph Moscato yes and we do have the best in my humble opinion

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Simply Good Foods Class Action: Deadline Nears

Updated Category News Views 2

Turning Points in the Simply Good Foods Saga Investing always comes with its share of heartaches, but when a company's strategic blunders land you in hot water, it's personal. Simply Good Foods (NASDAQ: SMPL) finds itself in the legal spotlight, with upcoming deadlines that investors should circle in red. If you took a hit with SMPL between October 24, 2024, and April 8,...

Continue Reading
Tetragon Completes $50M Tender Offer; Shares Prorated

Updated Category News Views 6

Unpacking Tetragon’s $50 Million Dutch Auction Move If you comb through the smoke-filled corridors of finance, you'll find the name Tetragon Financial Group pacing the latest tender offer rounds. They danced their way through a $50 million 'modified Dutch auction,' snapping up non-voting shares with a kind of ruthless efficiency that only seasoned market players can...

Continue Reading
GlocalMe Unveils Mobile Connectivity Innovations at IFA 2026

Updated Category News Views 3

Stepping into the Connectivity Future at IFA 2026 GlocalMe, a name synonymous with global mobile connections, made a splash at the IFA 2026 in Berlin. Equipped with a lineup built for the future, their presentation focused on lifestyle gadgets designed for constant online access. In a world where digital connection feels as vital as air, they've aligned perfectly with the...

Continue Reading
ToolDance X1 CNC Mill Unveils at IFA 2026

Updated Category News Views 1

IFA 2026 Reveals a Game Changer: ToolDance X1 Listen up, because ToolDance just threw a curveball into the CNC world with the launch of their X1 Smart Desktop CNC Mill at the IFA 2026 in Berlin. This isn't just another gadget—it's a real player aiming to bring manufacturing muscle right to your desktop. Will Wang, the genius behind ToolDance, wants to democratize CNC...

Continue Reading
Solomon e3 Halves Cloud Costs with NexQloud Shift

Updated Category News Views 3

Ever feel like you're drowning in an unnecessary cloud bill? Well, Solomon e3 did something about it. They chopped over half of their cloud spending after partnering with NexQloud. This isn't just an old-school belt-tightening; it's a full-on digital revamp after a deep-dive into their IT finances. Saving Pennies and Dollars with Smart Moves You'd think an energy company...

Continue Reading
Bybit Enhances BTC Staking Yields Amid Crypto Fluctuations

Updated Category News Views 2

An Uptick in BTC Staking Yields Seems like Bybit's got a trick up their sleeve with their latest move. They've hiked BTC staking yields from a static 0.8% up to a more attractive 1.2%. Now, if you're parked with Bitcoin in this dicey market, that's a substantial 50% leap upwards. When you think about those dreamy numbers traders like me fantasize about, it’s a juicy...

Continue Reading
Dimerix Locks Down A$34M Loan: No Shareholder Dilution

Updated Category News Views 2

Dimerix Grabs Non-Dilutive Funds amid Kidney Trials Here we go with Dimerix's latest move, folks. They roped in A$34 million through a cozy get-together with lenders from Australia and the U.S. What's the kicker? This cash won't touch shareholder equity. So, breathe easy, investors. It's a rare feat to pull off non-dilutive funds these days, especially in the biopharma...

Continue Reading
Midea Unveils SMART MASTER at IFA 2026: AI in Action

Updated Category News Views 2

Introduction: Midea Takes the Stage at IFA 2026 Ah, the glitz of a tech expo. This time around, Midea's making waves at IFA 2026. Their SMART MASTER system could be another notch in their belt if they pull off this seamless AI integration they keep yapping about. It's all about creating a home ecosystem that feels like it's actually got a brain—or so they say. Let's dig...

Continue Reading
Postal Service Defends New Rule Amid Speculation

Updated Category News Views 3

USPS Navigates Election Mail Controversies The U.S. Postal Service has found itself in the eye of a political storm, thanks to the latest Federal Ballot Mail Rule. Led by Postmaster General David Steiner, the USPS is setting the record straight amidst swirling misinformation and skepticism about its recent actions. This is not just a postal service under scrutiny—it's a...

Continue Reading
Labcorp Faces Lawsuit: Wiretapping Accusations Surface

Updated Category News Views 2

Labcorp's Legal Tangle Unveiled One minute you're on Labcorp's website searching for medical info, the next you're caught up in a class-action legal whirlwind. Legal drama is not on any patient’s checklist, but here we are, with Labcorp knee-deep in some serious allegations. The crux of the matter points to alleged wiretapping violations, with claims that Labcorp,...

Continue Reading

Top 5 Most Recently Viewed Articles

Potential Class Action Against Fluor Corporation by Investors

Updated Category News Views 174

Investors' Opportunity Amid Securities Concerns In recent news, investors have an encouraging opportunity regarding Fluor Corporation (NYSE: FLR). A national shareholder rights litigation firm is representing those affected by potential securities fraud within the company. This situation highlights the importance of investor awareness and timely action. Class Action...

Continue Reading
Caribou Biosciences' Leadership Joins Citi Biopharma Conference

Updated Category News Views 116

Caribou Biosciences' Participation in Important Biopharma Event Caribou Biosciences, Inc. (Nasdaq: CRBU), a pioneering company in CRISPR gene editing, recently announced that Rachel Haurwitz, PhD, the company’s president and CEO, will be engaging in a discussion at a prominent biopharma conference. The event, known as the Citi 2025 Biopharma Back to School Conference,...

Continue Reading
Glytec and Ardent Forge Alliance for Enhanced Diabetes Care

Updated Category News Views 50

Back in 2024, Glytec partnered with Ardent Health to tackle the diabetes epidemic affecting over 37 million Americans. Now, you know how these collaborations can go—everyone's excited at first, but when you dig into the numbers and outcomes, things can get murky real quick. They claimed they’d improve patient safety and clinical results while also cutting costs for...

Continue Reading
Exclusive Auction Features In-Demand Crypto and Token Domains

Updated Category News Views 261

Exclusive Auction Features In-Demand Crypto and Token Domains Bidding Open Now at bid.rotd.com | Lots Begin Closing Soon RightOfTheDot, a leading player in the domain auction industry, has unveiled an exclusive online auction that is generating considerable interest among investors and entrepreneurs alike. This specialized auction features an enticing lineup of coveted...

Continue Reading
Baiya International Group Celebrates Successful IPO Closing

Updated Category News Views 216

Baiya International Group Achieves Milestone with IPO Success Today, Baiya International Group Inc. (“BIYA”) announced a significant achievement in its business journey by successfully closing an initial public offering (IPO) of 2,500,000 ordinary shares at an offering price of $4.00 per share. This monumental move has garnered a gross amount of $10 million for the...

Continue Reading